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Gastric cancer is the forth most frequent malignancy and the second most common cause of cancer death worldwide. DNA
methylation is the most studied epigenetic alteration, occurring through a methyl radical addition to the cytosine base adjacent
to guanine. Many tumor genes are inactivated by DNA methylation in gastric cancer. We evaluated the DNA methylation status
of ANAPC1, CDKN2A and TP53 by methylation-specific PCR in 20 diffuse- and 26 intestinal-type gastric cancer samples and
20 normal gastric mucosa in individuals from Northern Brazil. All gastric cancer samples were advanced stage adenocarcino-
mas. Gastric samples were surgically obtained at the João de Barros Barreto University Hospital, State of Pará, and were stored
at -80°C before DNA extraction. Patients had never been submitted to chemotherapy or radiotherapy, nor did they have any other
diagnosed cancer. None of the gastric cancer samples presented methylated DNA sequences for ANAPC1 and TP53. CDKN2A
methylation was not detected in any normal gastric mucosa; however, the CDKN2A promoter was methylated in 30.4% of gastric
cancer samples, with 35% methylation in diffuse-type and 26.9% in intestinal-type cancers. CDKN2A methylation was
associated with the carcinogenesis process for ~30% diffuse-type and intestinal-type compared to non-neoplastic samples.
Thus, ANAPC1 and TP53 methylation was probably not implicated in gastric carcinogenesis in our samples. CDKN2A can be
implicated in the carcinogenesis process of only a subset of gastric neoplasias.
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Introduction
Gastric cancer is the forth most frequent malignancy
and the second most common cause of cancer death
worldwide (1). In Northern Brazil, gastric cancer is the
second most frequent neoplasia in males (11/100,000)
and the third most common in females (6/100,000) (2). Diet
may be associated with the high incidence of this neopla-
sia in the State of Pará, especially because of the high
consumption of salt-preserved food, low use of refrigera-
tors and low consumption of fresh fruit and vegetables (3).
DNA methylation is the most studied epigenetic altera-
tion, occurring by the addition of a methyl radical to the
cytosine base adjacent to guanine (4). In cancer, DNA
methylation of the promoter region of a normal tumor-
suppressor gene leads to the aberrant silencing of its
functions.
Three genes were chosen for evaluation considering
their function and/or their potential role in gastric carcino-
genesis: ANAPC1, CDKN2A and TP53.
Our group previously described a line of adenocar-
cinoma cells in which polyploidization due to endoredupli-
cation was detected (5). Atkin (6) suggested that polyploi-
dization could be a characteristic of carcinogenesis be-
cause the aggressiveness of a cancer is related to the
degree of genomic instability associated with chromo-
some selection. This genomic instability is a frequent find-
ing in gastric cancer (7). Accurate segregation of sister
chromatids during mitosis is necessary to prevent the
aneuploidy found in many cancers. The spindle check-
point has been shown to be defective in cancers with
chromosomal instability.
This checkpoint regulates the anaphase-promoting
complex or cyclosome. The product of ANAPC1 is the
largest subunit of the anaphase-promoting complex (8).
Thus, ANAPC1 may be a possible candidate for causing
the chromosomal instability seen in gastric cancer. How-
ever, the methylation pattern of ANAPC1 had never been
described. The product of CDKN2A is a protein that regu-
lates phosphorylation of the retinoblastoma protein and
negatively regulates the G1-S transition in the cell cycle
(9). CDKN2A hypermethylation may play a key role in the
progress of gastric cancer (10,11). TP53 is one of the most
studied tumor-suppressor genes and acts especially in cell
cycle arrest and induction of apoptosis (12). Inactivation of
the TP53 pathway is a common feature of neoplasia.
Dysregulation of the TP53 pathway has been shown to
involve mutations of TP53, increased expression of the
TP53 inhibitor HDM-2, or epigenetic silencing of the TP53
promoter (13). However, its methylation status has never
been studied in gastric carcinogenesis.
In the present study, we evaluated the methylation
status of ANAPC1, CDKN2A and TP53 promoters in gas-
tric adenocarcinoma samples and their possible associa-
tions with clinical and pathological characteristics, such as
gender, age, histopathology, tumor extension, and pres-
ence of lymph node or distant metastasis.
Material and Methods
Samples
The study included 66 samples of gastric tissue. Of 66
patients, 47 were male and 19 were female, and mean age
was 59 ± 9.8775 years (range 27–76). Among gastric
cancer samples, 20 were non-neoplastic gastric mucosa
of gastric cancer patients (distant location of primary tu-
mor) and 46 sporadic gastric adenocarcinoma samples.
Gastric samples were surgically obtained at the João de
Barros Barreto University Hospital (HUJBB), State of Pará,
Brazil, and were stored at -80°C before DNA extraction.
Patients had never been submitted to chemotherapy or
radiotherapy prior to surgery, nor did they have any other
diagnosed cancer. All patients signed an informed consent
with the approval of the HUJBB and Ribeirão Preto Medi-
cal School Clinical Hospital Institutional Review Board. All
46 gastric cancer samples were classified according to
Laurén (14): 20 were diffuse-type and 26 were intestinal-
type. Tumors were staged using standard criteria by tu-
mor, node, metastasis (TNM) staging (15).
Methylation-specific PCR
Genomic DNA (2 µg) was modified by bisulfite treat-
ment, converting unmethylated cytosines to uracils and
leaving methylated cytosines unchanged. Methylation-spe-
cific PCR (MSP) was performed on treated DNA as previ-
ously described (16). Specific primers for MSP (Table 1),
located within CpG island in the gene promoter region,
were designed with the assistance of the Methprimer soft-
ware (17).
The PCR product was carried out in a volume of 50 µL
with 200 µM dNTPs, 200 µM MgCl2, 50 ng DNA, 200 pM
primers, and 1 unit AmpliTaq GOLD (Applied Biosystems,
Foster City, CA, USA). After initial denaturing for 2 min at
94°C, 35 cycles at 94°C for 40 s, 1 min at different tempera-
tures with the primers (Table 1) and 72°C for 40 s were
followed by a final extension for 5 min at 72°C. PCR
products were separated and visualized by electrophore-
sis on 8% polyacrylamide gel and stained with 10% silver
nitrate (Figure 1). Water was used as negative control.
MSP results were scored when there was a clearly visible
band on electrophoresis gel with the methylated and un-
methylated primers (16).
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Statistical analysis
Statistical analyses were performed using the Fisher
exact test to assess associations between methylation sta-
tus and frequency, and clinical and pathological characteris-
tics, such as gender, age, histopathology, tumor extension,
and presence of lymph node or distant metastasis. P values
less than 0.05 were considered to be significant.
Results
According to Laurén’s classification (14), 20 were dif-
fuse-type and 26 were intestinal-type. All gastric cancer
samples were in advanced stage: 0% was at pT1, 26.1%
were at pT2, 63% were at pT3, and 10.9% were at pT4. It
was observed that 34.8% were at N0 stage, 58.7% at N1
Figure 1. Gel electrophoresis using ANAPC1, CDKN2A and
TP53 methylation-specific polymerase chain reaction primers. L:
size marker; M: methylated; U: unmethylated.
Table 1. Primer sequences (5'-3') for methylation-specific polymerase chain reaction.
Gene Sense Antisense Product size Temp.
ANAPC1 M: TTTAAGTTGTAATTCGTCGC M: TAACAAAAAAACGTACGAAAC 157 bp 52°C
U: TTTAAGTTGTAATTTGTTGTGG U: TAACAAAAAAACATACAAAACAT 157 bp
CDKN2A M: GTAGGGTTTAGAGTCGTTTCGA M: AACTACAAACTAAAACCCACGC 162 bp 55°C
U: CGTAGGGTTTAGAGTTGTTTTGA U: AACTACAAACTAAAACCCACACA 163 bp
TP53 M: CGTCGTATTTCGGATTAGATTTC M: AAAAAAACGTAAACGCTTCTCG 166 bp 57°C
U: GGTTGTTGTATTTTGGATTAGATTTT U: AAAAAAAACATAAACACTTCTCACC 170 bp
M = methylated sequence; U = unmethylated sequence; Temp. = melting temperature.
Table 2. Methylation number and frequency of CDKN2A in gas-
tric samples for comparison of gastric cancer with non-neoplas-
tic samples.
Samples Methylation status of CDKN2A P
M U
Normal (N = 20) 0 (0%) 20 (100%) -
Cancer (N = 46) 14 (30.4%) 32 (69.6%) 0.0009
Diffuse (N = 20) 7 (35%) 13 (65%) 0.0024
Intestinal (N = 26) 7 (26.9%) 19 (73.1%) 0.0137
Data are reported as number of individuals with percent within
parentheses. M = methylated; U = unmethylated. Fisher exact
test was used for statistical analysis.
and 6.5% at N2. No sample had distant metastasis.
None of the non-neoplastic samples showed methyla-
tion of any gene promoter. Furthermore, none of the samples
showed methylated sequences for the ANAPC1 and TP53
promoters. The methylation frequency of CDKN2A pro-
moter was 30.43% in gastric cancer samples. CDKN2A
methylation was associated with gastric cancer samples
compared to non-neoplastic samples (P = 0.0009).
CDKN2A methylation was associated with both diffuse-
type and intestinal-type compared to control samples us-
ing the Fisher exact test (P = 0.0024 and P = 0.0137,
respectively; Table 2).
We analyzed whether CDKN2A methylation was asso-
ciated with clinical and pathological characteristics, and
detected a tendency for this gene methylation in intestinal-
type gastric cancer with smaller tumor extension (T2)
compared to T3 and T4 stages (P = 0.0572).
Discussion
DNA methylation is a stable but reversible epigenetic
signal that silences gene expression. Somatic alterations
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in genomic methylation patterns contribute to the etiology
of human cancers and aging. It is tightly interwoven with
the modification of histone tails and other epigenetic sig-
nals (18).
Lima et al. (5) developed and characterized cytogeneti-
cally a cell line called ACP01 from a gastric adenocarci-
noma. In ACP01, polyploidization due to endoreduplica-
tion was observed. The spindle checkpoint has been shown
to be defective in cancers with chromosomal instability.
This checkpoint regulates the anaphase-promoting com-
plex or cyclosome. ANAPC1 product is the largest subunit
of the anaphase-promoting complex (8). To our knowl-
edge, the methylation status of ANAPC1 has never been
evaluated. In the present study, we did not detect ANAPC1
methylation. Our findings suggest that the ANAPC1 meth-
ylation is probably not important for the control of the
chromosomal instability in our samples.
Methylation of the CDKN2A promoter was detected in
30.43% of gastric cancer samples, which was not signifi-
cantly different from frequencies previously described
(range 21 to 43%), and was also associated with carcino-
genesis process (19-22). Lee et al. (23) proposed that
CDKN2A methylation may contribute to the malignant trans-
formation of gastric precursor lesions. Tahara et al. (24)
also suggested that the evaluation of CDKN2A status can
help predict gastric cancer risk in non-neoplastic gastric
epithelium, because methylation levels of CDKN2A seem
to accumulate in the progression of gastric mucosa atro-
phy and intestinal metaplasia, and thus may be associated
with the presence of gastric cancer especially for intesti-
nal-type histopathology. In our sample, diet habits may
play a role in CDKN2A methylation especially in the begin-
ning of intestinal-type gastric cancer.
TP53 is one of the most studied tumor-suppressor
genes and acts especially in cell cycle arrest and induction
of apoptosis. TP53 is a gene related to the majority of
human cancers. Methylation of TP53 was reported as a
mechanism for its inactivation in some neoplasias, such as
acute lymphoblastic leukemia, multiple myeloma, malig-
nant glioma cells, and brain metastases of solid tumors
(13,25-27). To our knowledge, the methylation status of
TP53 has never been evaluated in gastric samples. In the
present study, we did not detect TP53 methylation. Thus,
methylation of TP53 is not an important event for gastric
carcinogenesis in the population studied.
The identification of epigenetic modifications in tumor
suppressor genes and the determination of the frequency
of these alterations may be useful in the development of a
more specific cancer therapy.
This is the first study that evaluated the methylation
status of ANAPC1, CDKN2A and TP53 promoters in gas-
tric samples in a population from Northern Brazil. In this
study, the methylation pattern of ANAPC1 and TP53 pro-
moter was not altered by the gastric carcinogenesis pro-
cess. However, more studies are necessary to evaluate if
the absence of methylation of these genes is a common
finding in gastric cancer or if this is a regional characteristic.
CDKN2A promoter methylation was associated with
gastric carcinogenesis. However, only about 30% of gas-
tric cancer samples were methylated. CDKN2A methyla-
tion can be specific to a subset of gastric cancer and
probably plays a role in the beginning of intestinal-type
gastric cancer.
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